A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Summary

This is a Phase 1, two-part, open-label, nonrandomized, dose-escalation and signal-seeking study of CGT6297, evaluating the safety, tolerability, PK, pharmacodynamic (what the drug does to the body), and antitumor activity of CGT6297 in adult participants with advanced solid tumors harboring PIK3CA mutations

Timeline

Start

2026-06

Primary completion

2029-07

Completion

2029-08

Drugs

Indications